Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

C. Andronikou, K. Burdova, D. Dibitetto, C. Lieftink, E. Malzer, HJ. Kuiken, E. Gogola, A. Ray Chaudhuri, RL. Beijersbergen, H. Hanzlikova, J. Jonkers, S. Rottenberg

. 2024 ; 43 (6) : 1015-1042. [pub] 20240215

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006860

Grantová podpora
310030_179360 Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
P1BEP3_195482 Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
ERC-2019-AdG-883877 EC | European Research Council (ERC)
KFS-5519-02-2022 Krebsliga Schweiz (Swiss Cancer League)
2019.069.1 Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
KWF 2017-61169 KWF Kankerbestrijding (DCS)
KWF 2020-12894 KWF Kankerbestrijding (DCS)
22-00885S Grantová Agentura České Republiky (GAČR)

Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification of such vulnerabilities is of interest for targeting BRCA2;p53-deficient tumors that have acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) through loss of PARG expression. Here, by performing whole-genome CRISPR/Cas9 drop-out screens, we identify various genes involved in DNA repair to be essential for the survival of PARG;BRCA2;p53-deficient cells. In particular, our findings reveal EXO1 and FEN1 as major synthetic lethal interactors of PARG loss. We provide evidence for compromised replication fork progression, DNA single-strand break repair, and Okazaki fragment processing in PARG;BRCA2;p53-deficient cells, alterations that exacerbate the effects of EXO1/FEN1 inhibition and become lethal in this context. Since this sensitivity is dependent on BRCA2 defects, we propose to target EXO1/FEN1 in PARPi-resistant tumors that have lost PARG activity. Moreover, EXO1/FEN1 targeting may be a useful strategy for enhancing the effect of PARG inhibitors in homologous recombination-deficient tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006860
003      
CZ-PrNML
005      
20240423155536.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s44318-024-00043-2 $2 doi
035    __
$a (PubMed)38360994
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Andronikou, Christina $u Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland $u Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $u Oncode Institute, Amsterdam, The Netherlands $u Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland $1 https://orcid.org/0000000348458398
245    10
$a PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair / $c C. Andronikou, K. Burdova, D. Dibitetto, C. Lieftink, E. Malzer, HJ. Kuiken, E. Gogola, A. Ray Chaudhuri, RL. Beijersbergen, H. Hanzlikova, J. Jonkers, S. Rottenberg
520    9_
$a Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification of such vulnerabilities is of interest for targeting BRCA2;p53-deficient tumors that have acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) through loss of PARG expression. Here, by performing whole-genome CRISPR/Cas9 drop-out screens, we identify various genes involved in DNA repair to be essential for the survival of PARG;BRCA2;p53-deficient cells. In particular, our findings reveal EXO1 and FEN1 as major synthetic lethal interactors of PARG loss. We provide evidence for compromised replication fork progression, DNA single-strand break repair, and Okazaki fragment processing in PARG;BRCA2;p53-deficient cells, alterations that exacerbate the effects of EXO1/FEN1 inhibition and become lethal in this context. Since this sensitivity is dependent on BRCA2 defects, we propose to target EXO1/FEN1 in PARPi-resistant tumors that have lost PARG activity. Moreover, EXO1/FEN1 targeting may be a useful strategy for enhancing the effect of PARG inhibitors in homologous recombination-deficient tumors.
650    _2
$a lidé $7 D006801
650    12
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
650    _2
$a oprava DNA $7 D004260
650    _2
$a poškození DNA $7 D004249
650    12
$a nádory $x farmakoterapie $x genetika $7 D009369
650    _2
$a PARP inhibitory $x farmakologie $7 D000067856
650    _2
$a glykosidhydrolasy $x genetika $x metabolismus $7 D006026
650    _2
$a "flap" endonukleasy $x genetika $x metabolismus $x terapeutické užití $7 D045585
650    _2
$a exodeoxyribonukleasy $x genetika $7 D005090
650    _2
$a enzymy opravy DNA $x genetika $7 D045643
655    _2
$a časopisecké články $7 D016428
700    1_
$a Burdova, Kamila $u Laboratory of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic
700    1_
$a Dibitetto, Diego $u Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland $u Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland
700    1_
$a Lieftink, Cor $u Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $u The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands
700    1_
$a Malzer, Elke $u Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $u The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands
700    1_
$a Kuiken, Hendrik J $u Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $u The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $1 https://orcid.org/0000000210154607
700    1_
$a Gogola, Ewa $u Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands
700    1_
$a Ray Chaudhuri, Arnab $u Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015GD, Rotterdam, The Netherlands
700    1_
$a Beijersbergen, Roderick L $u Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands $u The Netherlands Cancer Institute Robotics and Screening Center, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands
700    1_
$a Hanzlikova, Hana $u Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland $u Laboratory of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic
700    1_
$a Jonkers, Jos $u Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl $u Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl $1 https://orcid.org/0000000292649792
700    1_
$a Rottenberg, Sven $u Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch $u Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch $u Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3088, Bern, Switzerland. sven.rottenberg@unibe.ch $1 https://orcid.org/0000000320449844
773    0_
$w MED00001509 $t EMBO journal $x 1460-2075 $g Roč. 43, č. 6 (2024), s. 1015-1042
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38360994 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155532 $b ABA008
999    __
$a ok $b bmc $g 2081063 $s 1216627
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 43 $c 6 $d 1015-1042 $e 20240215 $i 1460-2075 $m EMBO journal $n EMBO J $x MED00001509
GRA    __
$a 310030_179360 $p Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
GRA    __
$a P1BEP3_195482 $p Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
GRA    __
$a ERC-2019-AdG-883877 $p EC | European Research Council (ERC)
GRA    __
$a KFS-5519-02-2022 $p Krebsliga Schweiz (Swiss Cancer League)
GRA    __
$a 2019.069.1 $p Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
GRA    __
$a KWF 2017-61169 $p KWF Kankerbestrijding (DCS)
GRA    __
$a KWF 2020-12894 $p KWF Kankerbestrijding (DCS)
GRA    __
$a 22-00885S $p Grantová Agentura České Republiky (GAČR)
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace